Pfizer announces R&D and staff cuts upon Wyeth closing
This article was originally published in Scrip
Executive Summary
Pfizer says it will significantly reduce its R&D activities and staff less than a month after closing its $68 billion deal for Wyeth. The cuts came as a regulatory filing revealed that the firm axed around 6,500 employees in the first nine months of this year.